• Developing global, high-value products for patients with significant unmet medical needs in niche indications

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

IPO

IPO Calliditas Therapeutics